Drug intelligence / Profile preview

MT1013

Development stage: Phase 3
Lead developer: Shaanxi Micot Technology
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

MT1013 is a synthetic bispecific peptide drug candidate developed for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis. It acts as an agonist of the calcium-sensing receptor (CaSR), and is also described as a functional osteogenic growth peptide (OGP) analogue. The drug is administered intravenously and is currently being evaluated in phase II clinical trials to assess its efficacy and safety for SHPT in CKD patients on hemodialysis. The developer of MT1013 is Shaanxi Micot Technology[1][2][3][4][5].

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)CaSR (Extracellular calcium-sensing receptor)

Beyond the preview

Go deeper on MT1013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT1013.

Explore the full profile